Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g<i>BRCA1/2</i> Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer
AstraZeneca
Patricia A Ganz; Hanna Bandos; Tanja Španić; Sue Friedman; Volkmar Müller; Sherko Kuemmel; Suzette Delaloge; Etienne Brain; Masakazu Toi; Hideko Yamauchi; Eduardo-M de Dueñas; Anne Armstrong; Seock-Ah Im; Chuan-Gui Song; Hong Zheng; Tomasz Sarosiek; Priyanka Sharma; Cuizhi Geng; Peifen Fu; Kerstin Rhiem; Heike Frauchiger-Heuer; Pauline Wimberger; Daphné t'Kint de Roodenbeke; Ning Liao; Annabel Goodwin; Camille Chakiba-Brugère; Michael Friedlander; Keun Seok Lee; Sylvie Giacchetti; Toshimi Takano; Fernando Henao-Carrasco; Shamsuddin Virani; Frances Valdes-Albini; Susan M Domchek; Charles Bane; Edward C McCarron; Monica Mita; Giovanna Rossi; Priya Rastogi; Anitra Fielding; Richard D Gelber; Elsemieke D Scheepers; David Cameron; Judy Garber; Charles E Geyer; Andrew N J Tutt